View Older Stories
-
Alnylam Pharmaceuticals (ALNY) PT Lowered to $447 at Bernstein SocGen Group
-
Alnylam Pharma (ALNY) Tops Q1 EPS by 108c, provides guidance
-
U.S. Biotech stocks: Q1 earnings previews
-
Alnylam Pharmaceuticals (ALNY) PT Lowered to $448 at Bernstein SocGen
-
Alnylam presents cardiovascular drug data at medical conference
-
H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Stifel on Alnylam Pharmaceuticals (ALNY): 'positively biased after the pullback'
-
BofA on Alnylam (ALNY): 'AI-enabled diagnostics will help increase diagnosis rates'
-
Morgan Stanley: 'we see Amvuttra as well positioned'
-
Alnylam partners with Viz.ai and American Heart Association on ATTR-CM care
-
Jefferies Downgrades Alnylam Pharmaceuticals (ALNY) to Hold
-
Tenaya Therapeutics partners with Alnylam for heart disease targets
-
H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Freedom Capital Markets Upgrades Alnylam Pharmaceuticals (ALNY) to Buy
-
Alnylam Pharmaceuticals (ALNY) PT Lowered to $450 at RBC Capital
-
Alnylam Pharmaceuticals (ALNY) PT Lowered to $460 at BofA Securities
-
Alnylam Pharma (ALNY) Tops Q4 EPS by 6c, Misses on Revenue; Offers FY26 Revenue Guidance
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $510 at H.C. Wainwright
-
Alnylam Pharmaceuticals (ALNY) PT Lowered to $465 at RBC Capital
-
Alnylam Pharmaceuticals (ALNY) Reiterated at Neutral by Cantor Fitzgerald
-
H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $529 at Needham
-
Alnylam Pharmaceuticals (ALNY) PT Lowered to $529 at BofA Securities
-
Raymond James Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY)
-
RBC Capital on Alnylam Pharmaceuticals (ALNY): '2026 Guide Meaningfully Ahead Of Consensus'
-
Goldman Sachs Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Oppenheimer Assumes Alnylam Pharmaceuticals (ALNY) at Perform
-
Alnylam Pharmaceuticals (ALNY) PT Lowered at Bernstein Ahead of Next Week's Preannouncement
-
Biotechnology: Here are Piper Sandler's Top Picks and Focus Names for 2026
-
Alnylam plans $250 million facility expansion for siRNA manufacturing
-
Western Digital stock rises after inclusion in Nasdaq-100 Index
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $508 at Stifel on Vutrisiran Success
-
H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Goldman Shuffles Monthly Director's Cut List for US Names
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $500 at Oppenheimer
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $472 at Raymond James
-
Alnylam Pharma (ALNY) Tops Q3 EPS by $2.38
-
Bernstein's US Biotech 3Q25 Preview: 'Expect Beats from ALNY and REGN'
-
Cantor Fitzgerald Reiterates Alnylam Pharmaceuticals (ALNY) at Neutral on Good Execution
-
Truist Securities: 'Is Biotech Back?!'
-
Biotech stocks: Q3 earnings preview
-
H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $495 at Stifel
-
Alnylam secures $500 million revolving credit facility
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $500 at RBC Capital
-
Alnylam joins Alliance for Genomic Discovery genomic dataset
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $470 at BMO Capital
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $470 at BMO Capital
-
H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Truist Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)

